Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://journals.lww.com/amjclinicaloncology/abstract/2008/06000/improvement,_clinical_course,_and_quality_of_life.16.aspx, but it redirected us to https://journals.lww.com/amjclinicaloncology/abstract/2008/06000/improvement,_clinical_course,_and_quality_of_life.16.aspx. The analysis below is for the second page.

Title[redir]:
American Journal of Clinical Oncology
Description:
ies were identified reporting on survival, progression, and quality of life endpoints including, but not limited to, EORTC QLQ-C30 questionnaire, clinical symptoms, and ability to reduce dexamethasone. Data from more than 300 GBM patients (grade 3 anaplastic gliomas were excluded) demonstrate that re-irradiation yields 6-month PFS of 28% to 39% and 1-year overall survival of 18% to 48%, without additional chemotherapy (median value 26%). Patients with Karnofsky performance status <70 appeared to be at higher risk of early progression and apparently had lesser benefit from re-irradiation. Clinical improvement was observed in 24% to 45% of the patients. Most studies suggest that stabilization of the performance status is a realistic aim. In the studies reporting on corticosteroid usage during and after re-irradiation, 20% to 60% of the patients achieved a reduction in steroid dependency. Serious late toxicity was uncommon, especially after conventional treatment and fractionated stereotactic radiotherapy (FSRT). In light of recent technological advances such as FSRT and intensity modulated radiotherapy, which permit maximal sparing of normal brain, re-treatment seems attractive, and deserves scientific validation. Even fraction sizes of 3 to 5 Gy seem to be well tolerated in limited-volume recurrences as long as the total dose is limited to 30 to 35 Gy. Salvage chemotherapy or targeted agents should be prospectively tested against re-irradiation alone....

Matching Content Categories {📚}

  • Education
  • TV
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?


Doi.org relies on MYBB.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,504,851 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

journal, reirradiation, patients, issue, clinical, access, log, subscribe, alerts, authors, abstract, radiotherapy, chemotherapy, studies, register, logo, articles, search, issues, review, article, improvement, quality, life, palliative, recurrent, glioblastoma, american, buy, gbm, reporting, survival, progression, limited, data, performance, status, fsrt, text, subscribers, request, browse, content, submit, service, privacy, policy, secondary, advanced, collections,

Topics {✒️}

eortc qlq-c30 questionnaire comprehensive literature search 0b013e31815e3fdc buy abstract journal authors submit institutional users access full text access recurrent supratentorial glioblastoma primary radiation therapy recent technological advances permit maximal sparing deserves scientific validation artificial intelligence training fractionated stereotactic radiotherapy intensity modulated radiotherapy etoc alerts life endpoints including limited-volume recurrences service request 800-638-3030 journal tables register subscribe individual subscribers log access log performance status issue journal website subscribe clinical improvement palliative radiotherapy center submit carsten md¶ palliative effect previously treated identified reporting reduce dexamethasone higher risk lesser benefit realistic aim corticosteroid usage steroid dependency late toxicity normal brain fraction sizes total dose targeted agents prospectively tested email inbox rights reserved clinical oncology 31 clinical symptoms additional chemotherapy

Questions {❓}

  • Not a Subscriber?

Social Networks {👍}(1)

External Links {🔗}(60)

Analytics and Tracking {📊}

  • Comscore
  • Google Analytics
  • Google Tag Manager

Libraries {📚}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw
  • Jsdelivr
  • Scite
  • Wolterskluwer

5.61s.